

Public Summary

Summary for ARTG Entry: 15590 SUISSE LIQUID CHLOROPHYLL 20mg/g Solution bottle

ARTG entry for Medicine
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 10/09/1991
Product category Medicine
Status Revoked
Approval area

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Products**1. LIQUID CHLOROPHYLL 20mg/g solution**

Product Type	Single Medicine Product	Effective date	28/09/2001
--------------	-------------------------	----------------	------------

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product Information**Container Information**

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size	Poison Schedule
500mL	Not scheduled. Not considered by committee

Components**1. Medicine Component**

Dosage Form	Oral Liquid, solution
Route of Administration	Oral
Visual Identification	Dark green aqueous liquid

Active Ingredients

Chlorophyll	20 mg/g
--------------------	---------

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Summary for ARTG Entry: 15598 SUISSE ZESTABS Tablet bottle

ARTG entry for Medicine

Sponsor Swisse Wellness Pty Ltd

Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
Australia

ARTG Start Date 10/09/1991

Product category Medicine

Status Revoked

Approval area

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

The label of this product's container and primary pack (if any) is to carry the following statement 'Warning - this product contains royal jelly and is not recommended for asthma and allergy sufferers as it can cause severe allergic reactions'.

Products**1. Zestabs Tablet**

Product Type Single Medicine Product **Effective date** 27/03/1995

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product Information**Container Information**

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size
100 tablets

Poison Schedule
Not scheduled. Not considered by committee

Components**1. Medicine Component**

Dosage Form

Tablet, uncoated

Route of Administration

Oral

Visual Identification

Tablet, round, convex faces, diameter 11.17 mm, brown speckled

Active Ingredients

Centella asiatica	25 mg
Eleutherococcus senticosus	10 mg
Pollen	150 mg
Royal jelly	16.7 mg
Smlax species	37.5 mg

Public Summary

Public Summary

Summary for ARTG Entry: 15597 SWISSE WOMEN'S MULTI-VITAMIN & MINERAL FORMULA Tablet bottle

ARTG entry for Medicine

Sponsor Swisse Wellness Pty Ltd

Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
Australia

ARTG Start Date 10/09/1991

Product category Medicine

Status Revoked

Approval area

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989".

The label of this product's container and primary pack (if any) is to carry the following statement 'Warning - this product contains royal jelly and is not recommended for asthma and allergy sufferers as it can cause severe allergic reactions'.

Products

1. WOMEN'S MULTI-VITAMINS & MINERAL FORMULA Tablet

Product Type Single Medicine Product Effective date 1/04/1997

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product Information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison information

Pack Size

60 tablets

Poison Schedule

Not scheduled. Not considered by committee

Components

1. Medicine Component

Dosage Form

Tablet, film coated

Route of Administration

Oral

Visual Identification

Tablet, film-coated, oval with convex faces, approx. 24mm long x 11mm wide, approx. 1500mg, opaque apricot colour.

Active Ingredients

Aminobenzoic acid	25 mg
Berberis vulgaris	15 mg
Betacarotene	10 mg
Bioflavonoids	25 mg
Biotin	50 microgram
Calcium ascorbate	200 mg
Calcium citrate	200 mg
Calcium pantothenate	75 mg
Carica papaya	5 mg
Centella asiatica	2.5 mg
Chlorophyllin-copper complex	5 mg
Cholecalciferol	201.4 IU
Choline bitartrate	25 mg

Chromium amino acid chelate	10 microgram
Copper amino acid chelate	417 microgram
Cyanocobalamin	75 microgram
d-alpha-Tocopheryl acid succinate	83 mg
Equisetum arvense	6 mg
Evening Primrose Oil	10 mg
Ferrous fumarate	15.2 mg
Foeniculum vulgare	15 mg
Folic acid	180 microgram
Ginger	15 mg
Ginkgo biloba	625 microgram
Inositol	25 mg
Magnesium oxide	85 mg
Manganese amino acid chelate	8 mg
Matricaria recutita	15 mg
Mentha X cardiaca	1.5 mg
Nicotinamide	50 mg
Oryzanol	1 mg
Panax ginseng	8.3 mg
Petroselinum crispum	5 mg
Potassium amino acid chelate	10 mg
Potassium iodide	66 microgram
Pyridoxine hydrochloride	50 mg
Raspberry	15 mg
Riboflavine	25 mg
Royal jelly	7 mg
Silica - colloidal anhydrous	50 mg
Thiamine hydrochloride	50 mg
Ubidecarenone	1 mg
Zinc amino acid chelate	25 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Summary for ARTG Entry: 15595 SUISSE ULTI C Tablet bottle

ARTG entry for Medicine

Sponsor Swisse Wellness Pty Ltd

Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
Australia

ARTG Start Date 10/09/1991

Product category Medicine

Status Revoked

Approval area

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Products**1. Ulti C tablet**

Product Type	Single Medicine Product	Effective date	27/03/1995
---------------------	-------------------------	-----------------------	------------

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product Information**Container Information**

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size	Poison Schedule
50 tablets	Not scheduled. Not considered by committee

Components**1. Medicine Component****Dosage Form**

Tablet, film coated

Route of Administration

Oral

Visual Identification

Tablet, capsule shape 22.8 mm long x 9.4 mm wide, convex faces, film coated, cream colour, mottled.

Active Ingredients

Bioflavonoids	100 mg
Calcium ascorbate	1000 mg
Calcium carbonate	41.3 mg
Hesperidin	25 mg
Rutin	25 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Summary for ARTG Entry: 15593 SUISSE ULTI B COMPLEX Tablet bottle

ARTG entry for Medicine
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 10/09/1991
Product category Medicine
Status Revoked
Approval area

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Products**1. Ulti B Complex Tablet**

Product Type Single Medicine Product **Effective date** 27/03/1995

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product Information**Container Information**

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size
30 tablets

Poison Schedule
Not scheduled. Not considered by committee

Components**1. SUISSE ULTI B COMPLEX Tablet**

Dosage Form	Tablet
Route of Administration	Oral
Visual Identification	Tablet, round diameter 10.9 mm, convex faces, coated brown (chocolate)

Active Ingredients

Aminobenzoic acid	50 mg
Ascorbic acid	100 mg
Biotin	50 microgram
Calcium pantothenate	50 mg
Choline bitartrate	50 mg
Cyanocobalamin	50 microgram
Folic acid	400 microgram
Inositol	100 mg
Methionine	50 mg
Nicotinamide	50 mg
Pyridoxine hydrochloride	50 mg
Riboflavin	50 mg
Thiamine hydrochloride	50 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

CANCELLED

Public Summary

Public Summary

Summary for ARTG Entry: 15592 SWISSE ODOURLESS GARLIC & HORSERADISH Capsule bottle

ARTG entry for Medicine
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 10/09/1991
Product category Medicine
Status Revoked
Approval area

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Products**1. SWISSE HORSERADISH & ODOURLESS GARLIC Capsule**

Product Type Single Medicine Product **Effective date** 25/11/1999

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product information**Container information**

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison information

Pack Size
75 capsules

Poison Schedule
Not scheduled. Not considered by committee

Components**1. Medicine Component**

Dosage Form

Capsule, hard

Route of Administration

Oral

Visual Identification

Hard capsule size 0 clear containing an off white powder

Active Ingredients

Allium sativum	250 mg
Allium sativum	83.4 mg
Althaea officinalis	20 mg
Althaea officinalis	5 mg
Armoracia rusticana	50 mg
Armoracia rusticana	250 mg
Betacarotene	1.5 mg
Calcium ascorbate	241 mg
Histidine	50 mg
Thymus vulgaris	20 mg
Trigonella foenum-graecum	5 mg
Trigonella foenum-graecum	20 mg

Public Summary

Summary for ARTG Entry:	15596	SUISSE ULTIMINERAL Tablet bottle
ARTG entry for	Medicine	
Sponsor	Swisse Wellness Pty Ltd	
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia	
ARTG Start Date	10/09/1991	
Product category	Medicine	
Status	Revoked	
Approval area		

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Products**1. SUISSE Ultimineral tablet bottle**

Product Type	Single Medicine Product	Effective date	16/10/1995
---------------------	-------------------------	-----------------------	------------

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product information**Container information**

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison information

Pack Size	Poison Schedule
100 tablets	Not scheduled. Not considered by committee

Components**1. Medicine Component**

Dosage Form	Tablet, uncoated
Route of Administration	Oral
Visual Identification	Tablet, capsule shaped, faces convex, grey, speckled, dimensions 17.3mm long x 6.9mm wide

Active Ingredients

Calcium amino acid chelate	350 mg
Chromium amino acid chelate	50 microgram
Copper amino acid chelate	2 mg
Ferrous fumarate	1.65 mg
Fucus vesiculosus	10 mg
Magnesium amino acid chelate	175 mg
Manganese amino acid chelate	5 mg
Potassium amino acid chelate	30 mg
Zinc amino acid chelate	10 mg

Public Summary

Summary for ARTG Entry: 15585 SWISSE HALIBUT LIVER OIL 145mg A PLUS D Capsule bottle

ARTG entry for Medicine
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 10/09/1991
Product category Medicine
Status Revoked
Approval area

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Products**1. SWISSE Halibut Liver Oil 145mg A Plus D capsule**

Product Type Single Medicine Product **Effective date** 21/07/1995

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product information**Container information**

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison information

Pack Size	Poison Schedule
100 capsules	Not scheduled. Not considered by committee

Components**1. Medicine Component**

Dosage Form	Capsule, soft
Route of Administration	Oral
Visual Identification	Capsule SEG (soft elastic gelatin), round seamed 4minim, colour clear white

Active Ingredients

Halibut-liver oil	145 mg
-------------------	--------

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Summary for ARTG Entry: 15589 SUISSE LIVER EXTRACT 400mg Tablet bottle

ARTG entry for Medicine
 Sponsor Swisse Wellness Pty Ltd
 Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
 ARTG Start Date 10/09/1991
 Product category Medicine
 Status Revoked
 Approval area

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Products

1. Liver Extract 400mg tablet

Product Type	Single Medicine Product	Effective date	27/03/1995
--------------	-------------------------	----------------	------------

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product Information

Container Information

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size
 70 tablets

Poison Schedule
 Not scheduled. Not considered by committee

Components

1. Medicine Component

Dosage Form

Tablet, uncoated

Route of Administration

Oral

Visual Identification

Tablet, oval, dimensions 23.4 mm long x 10.6 mm wide. Brown (light) with brown (dark) speckle.

Active Ingredients

Liver extract

400 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Summary for ARTG Entry: 15586 SUISSE HERBAL DIURETIC Tablet bottle

ARTG entry for Medicine

Sponsor Swisse Wellness Pty Ltd

Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
Australia

ARTG Start Date 10/09/1991

Product category Medicine

Status Revoked

Approval area

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Products

1. SUISSE Herbal Diuretic tablet

Product Type Single Medicine Product Effective date 28/09/1998

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size	Poison Schedule
60 tablets	Not scheduled. Not considered by committee

Components

1. Medicine Component

Dosage Form	Tablet, uncoated
Route of Administration	Oral
Visual Identification	Tablet, round, convex faces, diameter 12mm, green speckled.
Active Ingredients	
Arctostaphylos uva-ursi	50 mg
Equisetum arvense	77.5 mg
Juniperus communis	50 mg
Petroselinum crispum	300 mg
Potassium gluconate	25 mg

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Summary for ARTG Entry: 15581 SUISSE CO ENZYME Q 10 Capsule bottle

ARTG entry for Medicine
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 10/09/1991
Product category Medicine
Status Revoked
Approval area

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Products**1. CO ENZYME Q 10 Capsule**

Product Type Single Medicine Product **Effective date** 25/11/1999

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product Information**Container Information**

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size	Poison Schedule
75 capsules	Not scheduled. Not considered by committee

Components**1. Medicine Component**

Dosage Form	Capsule, hard
Route of Administration	Oral
Visual Identification	Two piece capsule (hard) clear size o filled with a cream powder

Active Ingredients

Calcium hydrogen phosphate	200 mg
dl-alpha tocopheryl acetate	10 IU
Magnesium phosphate	100 mg
Potassium chloride	50 mg
Ubidecarenone	12 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Summary for ARTG Entry: 15583 SUISSE GINKGO BILOBA 200mg Tablet bottle

ARTG entry for Medicine
 Sponsor Swisse Wellness Pty Ltd
 Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
 ARTG Start Date 10/09/1991
 Product category Medicine
 Status Revoked
 Approval area

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Products

1. Ginkgo Biloba Tablet

Product Type Single Medicine Product Effective date 27/03/1995

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product Information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size	Poison Schedule
90 tablets	Not scheduled. Not considered by committee

Components

1. Medicine Component

Dosage Form	Tablet, uncoated
Route of Administration	Oral
Visual Identification	Tablet, round, diameter 11.26 mm, convex faces, grey with brown mottles

Active Ingredients

Ginkgo biloba	200 mg
---------------	--------

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Summary for ARTG Entry: 15587 SUISSE INOSINE Tablet bottle

ARTG entry for Medicine

Sponsor Swisse Wellness Pty Ltd

Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
Australia

ARTG Start Date 10/09/1991

Product category Medicine

Status Revoked

Approval area

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Products**1. INOSINE tablet**

Product Type Single Medicine Product **Effective date** 16/10/1995

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product Information**Container Information**

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size	Poison Schedule
50 tablets	Not scheduled. Not considered by committee

Components**1. Medicine Component**

Dosage Form	Tablet, uncoated
Route of Administration	Oral
Visual Identification	Tablet, capsule shape convex faces, 22.6 mm x 9.3 9.3mm, white

Active Ingredients

Inosine	500 mg
Magnesium aspartate	30 mg
Potassium aspartate	10 mg

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Summary for ARTG Entry: 15588 SUISSE LIPOTROPIC FAT EMULSIFIERS Tablet bottle

ARTG entry for Medicine
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 10/09/1991
Product category Medicine
Status Revoked
Approval area

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Products**1. Lipotropic Fat Emulsifiers Tablet**

Product Type Single Medicine Product **Effective date** 16/10/1995

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product information**Container information**

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison information

Pack Size
 69 tablets,
 40 tablets

Poison Schedule
 Not scheduled. Not considered by committee,
 Not scheduled. Not considered by committee

Components**1. Medicine Component**

Dosage Form

Tablet, film coated

Route of Administration

Oral

Visual Identification

Tablet, capsule shape, dimensions 22.7 mm long x 9.3 mm wide. Convex faces, film coated. Light brown speckled.

Active Ingredients

Betaine hydrochloride	100 mg
Choline bitartrate	500 mg
Fucus vesiculosus	10 mg
Inositol	250 mg
Lecithin	20 mg
Liver extract	5 mg
Medicago sativa	10 mg
Methionine	100 mg
Pancreatin	20 mg
Pyridoxine hydrochloride	25 mg
Stellaria media	5 mg

written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

CANCELLED

Public Summary

Public Summary

Summary for ARTG Entry: 15582 SUISSE GARLIC & HORSERADISH COMPLEX Tablet bottle

ARTG entry for Medicine
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 10/09/1991
Product category Medicine
Status Revoked
Approval area

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Products**1. Garlic & Horseradish Complex Tablet**

Product Type Single Medicine Product **Effective date** 16/10/1995

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product information**Container information**

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison information

Pack Size
60 tablets

Poison Schedule

Not scheduled. Not considered by committee

Components**1. Medicine Component****Dosage Form**

Tablet, uncoated

Route of Administration

Oral

Visual Identification

Tablet, round, convex faces, diameter 12.08 mm, grey speckled

Active Ingredients

Allium sativum	167 mg
Althaea officinalis	12.5 mg
Armoracia rusticana	100 mg
Petroselinum crispum	50 mg
Trigonella foenum-graecum	50 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Summary for ARTG Entry: 15584 SUISSE HAIR & NAIL Tablet bottle

ARTG entry for Medicine
 Sponsor Swisse Wellness Pty Ltd
 Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
 ARTG Start Date 10/09/1991
 Product category Medicine
 Status Revoked
 Approval area

Conditions

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Conditions Applying to Therapeutic Goods Accepted for Registration or Listing as Goods Currently Supplied at the Commencement of the Therapeutic Goods Act 1989"

Products

1. Hair And Nail Tablet

Product Type Single Medicine Product Effective date 24/02/1995

Warnings

No Warnings included on Record

Standard Indications

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code)

Specific Indications

No Specific Indications included on Record

Additional Product Information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size	Poison Schedule
85 tablets	Not scheduled. Not considered by committee

Components

1. Medicine Component

Dosage Form	Tablet
Route of Administration	Oral
Visual Identification	Tablet, round, convex faces, diameter 11.3 mm, light green speckled
Active Ingredients	
Calcium hydrogen phosphate	424 mg
Equisetum arvense	230 mg
Magnesium oxide	8.3 mg
Silicon dioxide	25 mg

Public Summary

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Summary for ARTG Entry:	129846	SWISSE MEN'S ULTIVITE MULTIVITAMIN, MINERAL AND ANTI-OXIDANT FORMULA 1 WITH HERBS (CAPSULE)
ARTG entry for	Medicine Listed	
Sponsor	Swisse Wellness Pty Ltd	
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia	
ARTG Start Date	31/07/2006	
Product category	Medicine	
Status	Revoked	
Approval area	Listed Medicines	

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at <http://www.tga.gov.au/industry/cm-colourings-oral-use.htm>, as amended from time to time.

Products

1. SWISSE MEN'S ULTIVITE MULTIVITAMIN, MINERAL AND ANTI-OXIDANT FORMULA 1 WITH HERBS (CAPSULE)

Product Type	Single Medicine Product	Effective date	28/08/2009 9:44:39 AM
---------------------	-------------------------	-----------------------	-----------------------

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

Contains caffeine [state quantity per dosage unit or per mL or per gram of product] [must be clear and legible].,

This product contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.,

Do not take while on warfarin therapy without medical advice.,

Contains lactose (or words to that effect).

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Contains [insert name of ingredient] (or words to that effect).

Standard Indications

Source of folic acid. Can assist in maintaining normal blood.,

Source of folic acid. Can assist in maintaining normal blood. Blood tonic.,

Male support. Balances and supports normal male physiology and function.,

Aids, assists or helps in the maintenance or improvement of general well-being.,

Beneficial during times of stress. [Warning S required],

Helps relieve nervous tension, stress and mild anxiety. [Warning S required],

For mineral (may state the mineral) supplementation.,

For vitamin (may state the vitamin) supplementation.,

Prevention/treatment of vitamin [XX] and/or mineral [YY] and/or nutritional deficiencies (This indication is not be to used for the treatment of iron deficiency conditions).,

May assist in the management of dietary folate deficiency.

Specific Indications

Designed to meet men's nutritional needs and general well-being. The herbal ingredients in this formulation may help men perform in peak condition and improve stress adaptation.

Additional Product Information

Pack Size/Poison information

Pack Size

Components

1. COMPONENT ONE

Dosage Form

Route of Administration

Visual Identification

Active Ingredients

Apium graveolens

Equivalent: Apium graveolens (Dry)

Astragalus membranaceus

Equivalent: Astragalus membranaceus (Dry)

Avena sativa

Equivalent: Avena sativa (Fresh)

Barosma betulina

Equivalent: Barosma betulina (Dry)

Berberis vulgaris

Equivalent: Berberis vulgaris (Dry)

Biotin

Calcium ascorbate dihydrate

Calcium citrate

Calcium pantothenate

Camellia sinensis

Equivalent: Camellia sinensis (Dry)

Carica papaya

Centella asiatica

Equivalent: Centella asiatica (Dry)

Cholecalciferol

Choline bitartrate

Chromium picolinate

Citrus bioflavonoids extract

Copper gluconate

Crataegus monogyna

Equivalent: Crataegus monogyna (Dry)

Cyanocobalamin

Cynara scolymus

Equivalent: Cynara scolymus (Fresh)

d-alpha-Tocopheryl acid succinate

Dunaliella salina

Equisetum arvense

Equivalent: Equisetum arvense (Dry)

Ferrous fumarate

Foeniculum vulgare

Equivalent: Foeniculum vulgare (Dry)

Folic acid

Ginkgo biloba

Equivalent: Ginkgo biloba (Dry)

Inositol

Lutein

Lycopersicon esculentum

Lysine hydrochloride

Magnesium oxide - heavy

Poison Schedule

Capsule, hard

Oral

1 mg
10 mg
2.5 mg
25 mg
250 mg
1.25 mg
5 mg
1.25 mg
7.5 mg
25 microgram
100 mg
50 mg
35 mg
1.67 mg
10 mg
5 mg
6.25 mg
25 mg
.0025 mg
12.5 mg
25 microgram
20 mg
100 microgram
12.5 mg
50 mg
15 microgram
6.25 mg
25 mg
20.256 mg
3.75 mg
15 mg
4.8 mg
1.7 mg
7.5 mg
250 microgram
1 mg
50 mg
12.5 mg
100 microgram
25 mg
50 mg

Public Summary

Manganese amino acid chelate	6 mg
Nicotinamide	15 mg
Panax ginseng	8.33 mg
Equivalent: Panax ginseng (Dry)	25 mg
Petroselinum crispum	5 mg
Potassium iodide	33 microgram
Potassium sulfate	4.46 mg
Pyridoxine hydrochloride	15 mg
Riboflavine	15 mg
Selenomethionine	32.5 microgram
Serenoa repens	10 mg
Equivalent: Serenoa repens (Dry)	100 mg
Silybum marianum	357 microgram
Smilax officinalis	6.25 mg
Equivalent: Smilax officinalis (Dry)	25 mg
Spearmint Oil	750 microgram
Thiamine hydrochloride	15 mg
Turnera diffusa	12 mg
Equivalent: Turnera diffusa (Dry)	60 mg
Tyrosine	500 microgram
Ubidecarenone	500 microgram
Vaccinium myrtillus	
Vitis vinifera	4.17 mg
Zinc amino acid chelate	15 mg
Zingiber officinale	500 microgram
Equivalent: Zingiber officinale (Dry)	2.5 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Public Summary

Summary for ARTG Entry:	124329	Swisse Ultiboost Bone Dense
ARTG entry for	Medicine Listed	
Sponsor	Swisse Wellness Pty Ltd	
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia	
ARTG Start Date	19/12/2005	
Product category	Medicine	
Status	Revoked	
Approval area	Listed Medicines	

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at <http://www.tga.gov.au/industry/cm-colourings-oral-use.htm> as amended from time to time.

Products

1. Swisse Ultiboost Bone Dense

Product Type	Single Medicine Product	Effective date	31/05/2011 12:08:48 PM
---------------------	-------------------------	-----------------------	------------------------

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis in later life,
Source of calcium. A diet deficient in calcium can lead to osteoporosis in later life.

Specific Indications

Swisse Ultiboost Bone Dense is best taken at night because the mineral flux in your body that maintains bone growth is greatest during sleep. It has been shown that taking excessive amounts of calcium without the necessary supplementary nutrients may hinder the rate of calcium absorption. Swisse Ultiboost Bone Dense should be combined with weight bearing exercises, as determined by your Health Care Practitioner, to assist in increasing bone density to minimize the risk of osteoporosis in later life. Formulated to strengthen and protect bones and teeth

Additional Product Information

Container Information

Type	Material	Life Time	Temperature	Closure	Conditions
Jar/Can	Not recorded	Not recorded	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size

Poison Schedule

Components

1. Formulation 1

Dosage Form

Tablet, film coated

Route of Administration

Oral

Visual Identification**Active Ingredients**

Calcium ascorbate dihydrate	50 mg
Calcium carbonate	750 mg
Cholecalciferol	.012 mg
Chromic chloride	51 microgram
Copper gluconate	250 microgram
Magnesium aspartate	80 mg
Magnesium oxide - heavy	461.95 mg
Magnesium phosphate	150 mg
Manganese amino acid chelate	25 mg
Potassium aspartate	27.28 mg
Potassium iodide	66 microgram
Zinc sulfate monohydrate	33.34 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Public Summary

Summary for ARTG Entry: 122610 Swisse Men's Ultivite Multi-Vitamin Mineral & Anti-oxidant Formula 1 with herbs (tablets)

ARTG entry for Medicine Listed
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 12/10/2005
Product category Medicine
Status Revoked
Approval area Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at <http://www.tga.gov.au/industry/cm-colourings-oral-use.htm>, as amended from time to time.

Where the medicine is a conventional release folic acid supplement preparation, in tablet form, of strength of 100 micrograms or more per dosage unit, the additional conditions are as follows: Where the medicine contains folic acid as a single active ingredient, the dissolution characteristics for folic acid in this medicine must comply with the dissolution requirements in the United States Pharmacopoeia 24th Edition (USP24) monograph for Folic Acid Tablets. Where the medicine contains multiple active ingredients, the dissolution characteristics for folic acid in this medicine must comply with the dissolution requirements in the United States Pharmacopoeia 24th Edition (USP24) monograph for Nutritional Supplements, as amended by its First Supplement. The dissolution characteristics for this medicine must comply with the dissolution requirements of the relevant USP24 monograph over the shelf life of the product when stored under the conditions included on the product label. It is the responsibility of manufacturers to develop and validate the analytical methods for the determination of folic acid that should be used in conjunction with the USP24 dissolution criteria. This condition does not apply to chewable, effervescent or dispersible tablets or sustained release tablets.

Products

1. Swisse Men's Ultivite Multi-Vitamin Mineral & Anti-oxidant Formula 1 with herbs (tablets)

Product Type Single Medicine Product **Effective date** 28/08/2009 9:44:39 AM

Warnings

Contains [insert name of ingredient] (or words to that effect).,

Do not take while on warfarin therapy without medical advice.,

Contains lactose (or words to that effect).,

This product contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.,

Contains caffeine [state quantity per dosage unit or per mL or per gram of product] [must be clear and legible].,

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

Aids, assists or helps in the maintenance or improvement of general well-being.,

May assist in the management of dietary folate deficiency.,

Source of folic acid. Can assist in maintaining normal blood.,

Source of folic acid. Can assist in maintaining normal blood. Blood tonic.,

Male support. Balances and supports normal male physiology and function.,

Helps relieve nervous tension, stress and mild anxiety. [Warning S required],

Prevention/treatment of vitamin [XX] and/or mineral [YY] and/or nutritional deficiencies (This indication is not be used for the treatment of iron deficiency conditions),.

For vitamin (may state the vitamin) supplementation.,

For mineral (may state the mineral) supplementation.,

Beneficial during times of stress. [Warning S required]

Specific Indications

Designed to meet men's nutritional needs and general well-being. The herbal ingredients in this formulation may help men perform in peak condition and improve stress adaptation.

Additional Product information

Pack Size/Poison information

Pack Size

Components

1. COMPONENT ONE

Dosage Form

Route of Administration

Visual Identification

Active Ingredients

Apium graveolens

Equivalent: Apium graveolens (Dry)

Astragalus membranaceus

Equivalent: Astragalus membranaceus (Dry)

Avena sativa

Equivalent: Avena sativa (Fresh)

Barosma betulina

Equivalent: Barosma betulina (Dry)

Berberis vulgaris

Equivalent: Berberis vulgaris (Dry)

Biotin

Calcium ascorbate dihydrate

Calcium citrate

Calcium pantothenate

Camellia sinensis

Equivalent: Camellia sinensis (Dry)

Carica papaya

Centella asiatica

Equivalent: Centella asiatica (Dry)

Cholecalciferol

Choline bitartrate

Chromium picolinate

Citrus bioflavonoids extract

Copper gluconate

Crataegus monogyna

Equivalent: Crataegus monogyna (Dry)

Cyanocobalamin

Cynara scolymus

Equivalent: Cynara scolymus (Fresh)

d-alpha-Tocopheryl acid succinate

Dunaliella salina

Equisetum arvense

Equivalent: Equisetum arvense (Dry)

Ferrous fumarate

Foeniculum vulgare

Equivalent: Foeniculum vulgare (Dry)

Folic acid

Ginkgo biloba

Poison Schedule

Tablet, film coated

Oral

2 mg
20 mg
5 mg
50 mg
500 mg
2.5 mg
10 mg
2.5 mg
15 mg
50 microgram
200 mg
100 mg
70 mg
3.34 mg
20 mg
10 mg
12.5 mg
50 mg
.005 mg
25 mg
50 microgram
40 mg
200 microgram
25 mg
100 mg
30 microgram
12.5 mg
50 mg
41.33 mg
7.5 mg
30 mg
9.61 mg
3.41 mg
15 mg
500 microgram
2 mg

Public Summary

Equivalent: Ginkgo biloba (Dry)	100 mg
Inositol	25 mg
Lutein	.2 mg
Lycopersicon esculentum	
Lysine hydrochloride	50 mg
Magnesium oxide - heavy	100 mg
Manganese amino acid chelate	12 mg
Nicotinamide	30 mg
Panax ginseng	16.67 mg
Equivalent: Panax ginseng (Dry)	50 mg
Petroselinum crispum	10 mg
Potassium iodide	66 microgram
Potassium sulfate	8.92 mg
Pyridoxine hydrochloride	30 mg
Riboflavine	30 mg
Selenomethionine	65 microgram
Serenoa repens	20 mg
Equivalent: Serenoa repens (Dry)	200 mg
Silybum marianum	715 microgram
Smilax officinalis	12.5 mg
Equivalent: Smilax officinalis (Dry)	50 mg
Spearmint Oil	1.7 mg
Thiamine hydrochloride	30 mg
Tocopherols concentrate - mixed (low-alpha type)	466.2 microgram
Turnera diffusa	24 mg
Equivalent: Turnera diffusa (Dry)	120 mg
Tyrosine	1 mg
Ubidecarenone	1 mg
Vaccinium myrtillus	
Vitis vinifera	8.34 mg
Zinc amino acid chelate	30 mg
Zingiber officinale	1 mg
Equivalent: Zingiber officinale (Dry)	5 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Summary for ARTG Entry: 123100 H BIO-JUVEN HAIR NAILS SKIN MINERAL & HERBAL FORMULA WITH ADDED VITAMINS

ARTG entry for Medicine Listed
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 26/10/2005
Product category Medicine
Status Revoked
Approval area Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at <http://www.tga.gov.au/industry/cm-colourings-oral-use.htm> as amended from time to time.

Products**1. H BIO-JUVEN HAIR NAILS SKIN MINERAL & HERBAL FORMULA WITH ADDED VITAMINS**

Product Type Single Medicine Product **Effective date** 28/08/2009 9:44:39 AM

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

Aids, assists or helps in the maintenance or improvement of general well-being.,

Aids or assists in the maintenance of peripheral circulation.

Specific Indications

H Bio-Juven contains vitamins and minerals known to science today to assist in making hair, nails and skin look and feel better, plus herbs to help aid in the maintenance of peripheral circulation so that these nutrients can travel to their destination and fulfil the desired objectives. To PERI and healthy hair, skin and nails.

Additional Product Information**Pack Size/Poison Information****Pack Size****Components****1. COMPONENT ONE****Dosage Form**

Capsule, hard

Route of Administration

Oral

Visual Identification**Active Ingredients**

Biotin

200 microgram

Calcium ascorbate dihydrate	60 mg
Calcium citrate	50 mg
Calcium pantothenate	25 mg
Cholecalciferol	.25 microgram
Citrus bioflavonoids extract	40 mg
Cyanocobalamin	25 microgram
Cysteine hydrochloride	60 mg
Cystine	20 mg
d-alpha-Tocopheryl acid succinate	10.0032 mg
Dunaliella salina	
Equisetum arvense	12.5 mg
Equivalent: Equisetum arvense (Dry)	50 mg
Ferrous fumarate	9.61 mg
Folic acid	50 microgram
Ginkgo biloba	10 mg
Magnesium oxide - heavy	51.82 mg
Nicotinamide	10 mg
Panicum miliaceum	25.46 mg
Potassium iodide	65.4 microgram
Pyridoxine hydrochloride	10 mg
Riboflavine	10 mg
Salvia officinalis	50 mg
Thiamine hydrochloride	10 mg
Zinc amino acid chelate	25 mg
Zingiber officinale	50 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Public Summary

Summary for ARTG Entry:	100430 Childvite 2
ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	29/03/2004
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1. Childvite 2

Product Type	Single Medicine Product	Effective date	4/10/2007 11:00:00 PM
---------------------	-------------------------	-----------------------	-----------------------

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

Aids, assists or helps in the maintenance or improvement of general well-being.

Specific Indications

A children's Multivitamin, Mineral & Antioxidant Formula with selected herbs to promote stamina, endurance and well-being. Swisse Childvite 2 Multivitamin, Mineral and Antioxidant Formula in powder form has been formulated specifically for children of all ages, including those who are too young to swallow or chew tablets. Childvite 2 has been specially formulated with selected vitamins, minerals, antioxidants and herbs to address the nutritional needs of children low in stamina and endurance. The vitamin, mineral and antioxidant ingredients have been added to assist in the promotion of general well-being, while the herbs promote stamina and endurance.

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1. Medicine Component

Dosage Form

Oral Liquid, powder for

Route of Administration

Oral

Visual Identification

Active Ingredients

Ascorbic acid	5 mg/g
Biotin	3 microgram/g
Calcium carbonate	5.25 mg/g
Calcium pantothenate	200 microgram/g
Citrus bioflavonoids extract	200 microgram/g

Cyanocobalamin	300 ng/g
Eleutherococcus senticosus	39 microgram/g
Equivalent: Eleutherococcus senticosus (Dry)	643.5 microgram/g
Ferrous sulfate - dried	700 microgram/g
Folic acid	1.5 microgram/g
Magnesium aspartate	2.4 mg/g
Manganese sulfate monohydrate	50 microgram/g
Nicotinamide	1 mg/g
Pyridoxine hydrochloride	200 microgram/g
Riboflavin sodium phosphate	130 microgram/g
Thiamine hydrochloride	100 microgram/g
Urtica dioica	200 microgram/g
Equivalent: Urtica dioica (Dry)	1 mg/g
Zinc sulfate monohydrate	1.1 mg/g

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Public Summary

Summary for ARTG Entry: 122391 SWISSE WOMEN'S ULTIVITE MULTI-VITAMIN MINERAL & ANTI-OXIDANT FORMULA 1 WITH HERBS (CAPSULE)

ARTG entry for Medicine Listed
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 4/10/2005
Product category Medicine
Status Revoked
Approval area Listed Medicines

Products

1. SWISSE WOMEN'S ULTIVITE MULTI-VITAMIN MINERAL & ANTI-OXIDANT FORMULA 1 WITH HERBS (CAPSULE)

Product Type Single Medicine Product **Effective date** 28/08/2009 9:44:39 AM

Warnings

Contains caffeine [state quantity per dosage unit or per mL or per gram of product] [must be clear and legible].
 Do not take while on warfarin therapy without medical advice.,
 If symptoms persist consult your healthcare practitioner (or words to that effect).,
 This product contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.,
 Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,
 Contains lactose (or words to that effect).

Standard Indications

Source of folic acid. Can assist in maintaining normal blood.,
 Source of folic acid. Can assist in maintaining normal blood. Blood tonic.,
 Helps relieve nervous tension, stress and mild anxiety. [Warning S required],
 Beneficial during times of stress. [Warning S required],
 For mineral (may state the mineral) supplementation.,
 For vitamin (may state the vitamin) supplementation.,
 Prevention/treatment of vitamin [XX] and/or mineral [YY] and/or nutritional deficiencies (This indication is not be to used for the treatment of iron deficiency conditions).,
 May assist in the management of dietary folate deficiency,
 Aids, assists or helps in the maintenance or improvement of general well-being.

Specific Indications

Designed to assist in meeting women's nutritional needs and maintaining general well-being. The herbal ingredients may help women perform in peak condition and improve stress adaptation.
 Assist in the relief of pre-menstrual symptoms/syndrome

Additional Product information**Pack Size/Poison information****Pack Size****Components****1. COMPONENT ONE****Dosage Form****Route of Administration****Visual Identification****Active Ingredients****Apium graveolens**

Equivalent: Apium graveolens (Dry)

Arctostaphylos uva-ursi

Equivalent: Arctostaphylos uva-ursi (Dry)

Astragalus membranaceus

Equivalent: Astragalus membranaceus (Dry)

Avena sativa**Poison Schedule**

Capsule, hard

Oral

1 mg

10 mg

3.12 mg

12.5 mg

2.5 mg

25 mg

25 mg

Equivalent: Avena sativa (Fresh)	250 mg
Biotin	25 microgram
Calcium ascorbate dihydrate	100 mg
Calcium citrate	50 mg
Calcium pantothenate	37.5 mg
Camellia sinensis	1.67 mg
Equivalent: Camellia sinensis (Dry)	10 mg
Carica papaya	5 mg
Centella asiatica	1.25 mg
Equivalent: Centella asiatica (Dry)	5 mg
Cholecalciferol	.0025 mg
Choline bitartrate	12.5 mg
Chromium picolinate	25 microgram
Citrus bioflavonoids extract	20 mg
Copper gluconate	208.5 microgram
Crataegus monogyna	3.75 mg
Equivalent: Crataegus monogyna (Dry)	15 mg
Cyanocobalamin	25 microgram
Cynara scolymus	6.25 mg
Equivalent: Cynara scolymus (Fresh)	25 mg
d-alpha-Tocopheryl acid succinate	21.1 mg
Dunaliella salina	
Eleutherococcus senticosus	1.25 mg
Equivalent: Eleutherococcus senticosus (Dry)	12.5 mg
Equisetum arvense	3.75 mg
Equivalent: Equisetum arvense (Dry)	15 mg
Ferrous fumarate	7.94 mg
Foeniculum vulgare	1.7 mg
Equivalent: Foeniculum vulgare (Dry)	7.5 mg
Folic acid	250 microgram
Ginkgo biloba	50 microgram
Equivalent: Ginkgo biloba (Dry)	2.5 mg
Glycyrrhiza glabra	1.25 mg
Equivalent: Glycyrrhiza glabra (Dry)	5 mg
Inositol	12.5 mg
Lutein	100 microgram
Lycopersicon esculentum	
Lysine hydrochloride	25 mg
Magnesium oxide	42.5 mg
Manganese amino acid chelate	8 mg
Matricaria recutita	1.88 mg
Equivalent: Matricaria recutita (Dry)	7.5 mg
Nicotinamide	25 mg
Petroselinum crispum	5 mg
Potassium iodide	32.7 microgram
Potassium sulfate	2.23 mg
Pyridoxine hydrochloride	25 mg
Riboflavine	25 mg
Selenomethionine	32.5 microgram
Silybum marianum	357 microgram
Spearmint Oil	750 microgram
Thiamine hydrochloride	25 mg
Ubidecarenone	500 microgram
Vaccinium myrtillus	
Vitis vinifera	4.17 mg
Zinc amino acid chelate	12.5 mg
Zingiber officinale	1.5 mg

Equivalent: Zingiber officinale (Dry)

7.5 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

CANCELLED

Public Summary

Public Summary

Summary for ARTG Entry: 91326 Opticq

ARTG entry for Medicine Listed

Sponsor Swisse Wellness Pty Ltd

Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
Australia

ARTG Start Date 15/10/2002

Product category Medicine

Status Revoked

Approval area Listed Medicines

Products

1. Opticq

Product Type Single Medicine Product **Effective date** 3/04/2009 8:39:00 AM

Warnings

No Warnings included on Record

Standard Indications

Eyes formula. Assists visual fatigue and eye-strain.,
Eyes formula. Support of healthy eye function.,
Aids, assists or helps in the maintenance or improvement of general well-being.,
Maintenance of healthy eyes.,
Eyes formula. Helps eyes to adapt to variations in light intensity.

Specific Indications

CLINICALS OPTICQ by Swisse has been developed by a professor and contains scientifically validated ingredients to relieve visual fatigue and eye strain. It is recommended for people who experience problems with night vision and those sensitive to glare. OPTICQ is based on the assessment of clinical studies, which showed certain ingredients in OPTICQ to assist in promoting healthy vision. Used as directed, OPTICQ may deliver positive results relatively quickly. For better results: OPTICQ may be effective when used on it's own, however, we recommend you use this product in conjunction with Swisse Women's & Men's Ultivite, which act as a "foundation" to provide the body with the important nutrients necessary for general wellbeing.

Additional Product Information

Container Information

Type	Material	Life Time	Temperature	Closure	Conditions
SIMELOAD - missing code value	Not recorded	0 Unknown	SIMELOAD - missing code value	Not recorded	Not recorded

Pack Size/Poison Information

Pack Size

Not Applicable

Poison Schedule

Not scheduled. Not considered by committee

Components

1. Medicine Component

Dosage Form

Tablet, film coated

Route of Administration

Oral

Visual Identification

Information Not Provided

Active Ingredients

Calcium ascorbate	250 mg
Cupric sulfate pentahydrate	3.93 mg
d-alpha-Tocopheryl acid succinate	165.29 mg
Tagetes erecta	60 mg
Equivalent: Tagetes erecta (Dry)	330 mg
Tocopherols concentrate - mixed (low-alpha type)	378 mg
Zinc oxide	24.89 mg

Public Summary

Public Summary

Summary for ARTG Entry: 100431 Childvite 1

ARTG entry for Medicine Listed

Sponsor Swisse Wellness Pty Ltd

Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
Australia

ARTG Start Date 29/03/2004

Product category Medicine

Status Revoked

Approval area Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products**1. Childvite 1**

Product Type	Single Medicine Product	Effective date	4/10/2007 11:00:00 PM
--------------	-------------------------	----------------	-----------------------

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

Aids, assists or helps in the maintenance or improvement of general well-being.

Specific Indications

A children's Multivitamin, Mineral & Antioxidant Formula with selected herbs to promote calmness in very active children. Swisse Childvite 1 Multivitamin, Mineral and Antioxidant Formula in powder form has been formulated specifically for children of all ages, including those who are too young to swallow or chew tablets. Childvite 1 has been specifically formulated with selected vitamins, minerals, antioxidants and herbs to address the nutritional needs of very active children. These ingredients are known to be important for well-being and the herbs have been selected to promote calmness while relieving stress and nervous tension in very active children. Childvite 1 may also be used to assist the child to prepare for sleep. Childvite 1 has been developed by the Swisse team of medical researchers in consultation with parents to provide a pleasant tasting effervescent liquid with natural colours and flavours and no preservatives.

Additional Product Information**Pack Size/Poison information****Pack Size****Components****1. Medicine Component****Dosage Form****Route of Administration****Visual Identification****Active Ingredients**

Ascorbic acid

Biotin

Calcium carbonate

Poison Schedule

Oral Liquid, powder for

Oral

5 mg/g

3 microgram/g

5.25 mg/g

Calcium pantothenate	200 microgram/g
Citrus bioflavonoids extract	200 microgram/g
Cyanocobalamin	200 ng/g
Ferrous sulfate - dried	350 microgram/g
Folic acid	1 microgram/g
Humulus lupulus	57.14 microgram/g
Equivalent: Humulus lupulus (Dry)	200 microgram/g
Magnesium aspartate	2.4 mg/g
Manganese sulfate monohydrate	50 microgram/g
Matricaria recutita	375 microgram/g
Equivalent: Matricaria recutita (Dry)	1.5 mg/g
Nicotinamide	1 mg/g
Pyridoxine hydrochloride	300 microgram/g
Riboflavin sodium phosphate	160 microgram/g
Thiamine hydrochloride	150 microgram/g
Zinc sulfate monohydrate	1.1 mg/g

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Public Summary

Summary for ARTG Entry: 93095 Prosqn

ARTG entry for Medicine Listed

Sponsor Swisse Wellness Pty Ltd

Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
Australia

ARTG Start Date 18/02/2003

Product category Medicine

Status Revoked

Approval area Listed Medicines

Conditions

The listing of this medicine is subject to statutory conditions of listing and additional conditions of listing imposed by the Secretary under the provisions of subsection 28(3) of the Therapeutic Goods Act 1989 by notice in writing.

Products**1. Prosqn**

Product Type	Single Medicine Product	Effective date	4/10/2007 11:00:00 PM
--------------	-------------------------	----------------	-----------------------

Warnings

No Warnings included on Record

Standard Indications

For the symptomatic relief of medically diagnosed benign prostatic hypertrophy.,
Aids, assists or helps in the maintenance or improvement of general well-being.
May assist in the management of medically diagnosed benign prostatic hypertrophy.

Specific Indications

CLINICALS PROSQN by Swisse has been developed by a professor and contains scientifically validated ingredients, to assist in normal prostate function. PROSQN is based on the assessment of clinical studies, which showed certain ingredients in PROSQN to provide relief from the symptoms of medically diagnosed benign prostatic hypertrophy (or hyperplasia commonly known as prostate enlargement) such as difficulties in micturition, a hesitant interrupted weak stream, urinary frequency, urgency and dribbling or leaking. PROSQN is based on natural herbal ingredients. Used as directed, PROSQN may deliver positive results relatively quickly. For better results, PROSQN may be effective when used on it's own, however we recommend you use this product in conjunction with CLINICALS CEREXL and SWISSE MEN'S ULTIMITE FORMULA 1, which act as a "foundation" to provide the body with the important nutrients necessary for general wellbeing.

Additional Product Information**Container Information**

Type	Material	Life Time	Temperature	Closure	Conditions
SIMELOAD - missing code value	Not recorded	0 Unknown	SIMELOAD - missing code value	Not recorded	Not recorded

Pack Size/Poison information**Pack Size**

Not Applicable

Components**1. Medicine Component****Dosage Form****Poison Schedule**

Not scheduled. Not considered by committee

Route of Administration

Tablet, film coated

Visual Identification

Oral

Active Ingredients

Information Not Provided

Cholecalciferol	1.25 microgram
Cucurbita pepo	25 mg
Equivalent: Cucurbita pepo (Dry)	500 mg
Curcuma longa	4 mg
Equivalent: Curcuma longa (Dry)	100 mg
Folic acid	250 microgram
Ganoderma lucidum	2.75 mg
Equivalent: Ganoderma lucidum (Dry)	55 mg
Glycyrrhiza glabra	13.75 mg
Equivalent: Glycyrrhiza glabra (Dry)	55 mg

Isatis tinctoria	11 mg
Equivalent: Isatis tinctoria (Dry)	55 mg
Lycopersicon esculentum	10 mg
Equivalent: Lycopersicon esculentum (Fresh)	3.5 g
Panax ginseng	5.5 mg
Equivalent: Panax ginseng (Dry)	55 mg
Selenomethionine	16.25 microgram
Serenoa repens	100 mg
Equivalent: Serenoa repens (Dry)	1 g
Serenoa repens	217.5 mg
Equivalent: Serenoa repens (Dry)	870 mg
Urtica dioica	62.5 mg
Equivalent: Urtica dioica (Dry)	1.13 g
Zinc amino acid chelate	30 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright/htm>.

Public Summary

Public Summary

Summary for ARTG Entry:	120384 Venaxl
ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	6/07/2005
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Products

1. Venaxl

Product Type	Single Medicine Product	Effective date	3/04/2009 8:39:00 AM
---------------------	-------------------------	-----------------------	----------------------

Warnings

Do not take while on warfarin therapy without medical advice.,
 Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,
 This product contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.

Standard Indications

Protects capillaries.,
 Aids, assists or helps in the maintenance or improvement of general well-being.,
 Liver tonic.,
 Maintain health of capillaries.,
 Formula to support the liver.,
 May assist blood circulation.

Specific Indications

- Support for Healthy Heart & Cholesterol - CLINICALS: VENAXL by Swisse has been developed by a professor and contains scientifically validated ingredients that help maintain a healthy cardiovascular system. VENAXL assists in the maintenance of healthy heart tissue and function as well as protecting capillaries and helping maintain normal blood circulation. VENAXL also assists in the maintenance of healthy cholesterol level, which is so important for the overall wellbeing of the cardiovascular system. The liver plays a key role in the detoxification process and fat metabolism which assists in promoting healthy heart function. Therefore, VENAXL has been designed so that it also provides support for healthy liver function. VENAXL may deliver positive results relatively quickly. For better results: VENAXL may be effective when used on it's own, however we recommend you use this product in conjunction with Swisse Women's or Men's Ultivite which act as a "foundation" to provide the body with the important nutrients necessary for general well being. Has antioxidant action via its free radical scavenging properties.

Additional Product information

Pack Size/Poison information

Pack Size

Components

1. Medicine Component

Dosage Form

Route of Administration

Visual Identification

Active Ingredients

Calcium ascorbate	50 mg
Citrus bioflavonoids extract	20 mg
Crataegus monogyna	150 mg
Equivalent: Crataegus monogyna (Dry)	600 mg
Cyanocobalamin	25 microgram
Cynara scolymus	16.67 mg
Equivalent: Cynara scolymus (Fresh)	500 mg
d-alpha-Tocopheryl acid succinate	82.6464 mg
Folic acid	250 microgram
Levocarnitine	50 mg
Magnesium amino acid chelate	250 mg
Nicotinic acid	25 mg

Poison Schedule

Tablet, film coated

Oral

Pyridoxine hydrochloride

10 mg

Selenomethionine

16.25 microgram

Silybum marianum

21.43 mg

Ubidecarenone

25 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

CANCELLED

Public Summary

Public Summary

Summary for ARTG Entry:	92813 Cerexl
ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	3/02/2003
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Where the medicine is a conventional release folic acid supplement preparation in tablet form, of strength of 100 micrograms or more per dosage unit, the additional conditions are as follows: Where the medicine contains folic acid as a single active ingredient, the dissolution characteristics for folic acid in this medicine must comply with the dissolution requirements in the United States Pharmacopoeia 24th Edition (USP24) monograph for Folic Acid Tablets. Where the medicine contains multiple active ingredients, the dissolution characteristics for folic acid in this medicine must comply with the dissolution requirements in the United States Pharmacopoeia 24th Edition (USP24) monograph for Nutritional Supplements, as amended by its First Supplement. The dissolution characteristics for this medicine must comply with the dissolution requirements of the relevant USP24 monograph over the shelf life of the product when stored under the conditions included on the product label. It is the respo

Products

1. Cerexl

Product Type	Single Medicine Product	Effective date	4/10/2007 11:00:00 PM
---------------------	-------------------------	-----------------------	-----------------------

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

Standard Indications

Aids, assists or helps in the maintenance or improvement of general well-being.,

Aids or assists in the prevention of muscular cramps and spasms.,

Eyes formula. Support of healthy eye function.,

May assist in the management of tinnitus. [Warning S required],

May assist peripheral circulation.,

To help maintain blood circulation to the peripheral areas of the body such as the legs, hands and feet.,

Assisting in the maintenance of blood flow in the hands, feet and legs.,

For the symptomatic relief of tinnitus. [Warning S required]

Specific Indications

Support of Memory and Stamina CLINICALS CEREXL by Swisse has been developed by a professor and contains scientifically validated ingredients that help maintain memory function and stamina. CEREXL is based on the assessment of clinical studies, which showed certain ingredients in CEREXL can improve short-term memory and enhance mental alertness. CEREXL helps improve brain function such as learning or concentration as well as helping relieve the symptoms of absentmindedness. Used as directed, CEREXL may deliver positive results relatively quickly. For better results: CEREXL may be effective when used on it's own, however we recommend you use this product in conjunction with Swisse Women's or Men's Ultivite, which act as a foundation to provide the body with the important nutrients for general wellbeing. Reduces muscular pain and leg cramps and improves blood circulation. Relieves symptoms of cold hands and feet.

Additional Product information

Pack Size/Poison information**Pack Size****Components****1. Medicine Component****Dosage Form****Route of Administration****Visual Identification****Active Ingredients**

Calcium ascorbate dihydrate

Cyanocobalamin

Folic acid

Ginkgo biloba

Equivalent: Ginkgo biloba (Dry)

Glutamine

Lecithin liquid - soy phosphatidylserine-enriched soy

Levocarnitine

Magnesium aspartate

R,S-alpha Lipoic acid

Thiamine hydrochloride

Tyrosine

Zinc amino acid chelate

Poison Schedule

Tablet, film coated

Oral

60 mg

25 microgram

250 microgram

30 mg

1.5 g

125 mg

75 mg

50 mg

250 mg

75 mg

50 mg

50 mg

12.5 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Summary for ARTG Entry: 107806 Swisse Ultiboost Prostate

ARTG entry for Medicine Listed

Sponsor Swisse Wellness Pty Ltd

Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
Australia

ARTG Start Date 7/09/2004

Product category Medicine

Status Revoked

Approval area Listed Medicines

Products

1. Swisse Ultiboost Prostate

Product Type	Single Medicine Product	Effective date	29/06/2012
--------------	-------------------------	----------------	------------

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.

This product contains selenium which is toxic in high doses. A daily dose of 150 micrograms for adults of selenium from dietary supplements should not be exceeded.

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

For the symptomatic relief of medically diagnosed benign prostatic hypertrophy.,

May assist in the management of medically diagnosed benign prostatic hypertrophy.,

Aids, assists or helps in the maintenance or improvement of general well-being.

Specific Indications

Swisse Ultiboost PROSTATE is based on 25 years of research and contains scientifically validated ingredients, to assist in normal prostate function. Swisse Ultiboost PROSTATE is based on the assessment of clinical studies, which indicated that certain ingredients in the formula provided relief from the symptoms of medically diagnosed Benign Prostatic Hypertrophy (or Hyperplasia, commonly known as prostate enlargement), including difficulties in micturition, a hesitant interrupted weak stream, urinary frequency, urgency and dribbling or leaking. Swisse Ultiboost PROSTATE is based on natural herbal ingredients. Used as directed, Swisse Ultiboost PROSTATE may deliver positive results relatively quickly.

Additional Product information

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1. Formulation 1

Dosage Form

Tablet, film coated

Route of Administration

Oral

Visual Identification

Active Ingredients

Cholecalciferol	1.25 microgram
Cucurbita pepo	25 mg
Curcuma longa	25 mg
Folic acid	250 microgram
Ganoderma lucidum	2.75 mg
Glycyrrhiza glabra	13.75 mg
Isatis tinctoria	11 mg
Lycopersicon esculentum	10 mg
Panax ginseng	5.5 mg
Selenomethionine	16.25 microgram
Serenoa repens	217.5 mg
Serenoa repens	100 mg
Urtica dioica	62.5 mg
Zinc amino acid chelate	30 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

CANCELLED

Public Summary

Public Summary

Summary for ARTG Entry:	110295	SWISSE STUDENT HD
ARTG entry for	Medicine Listed	
Sponsor	Swisse Wellness Pty Ltd	
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia	
ARTG Start Date	28/09/2004	
Product category	Medicine	
Status	Revoked	
Approval area	Listed Medicines	

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at <http://www.tga.gov.au/industry/cm-colourings-oral-use.htm>, as amended from time to time.

Products

1. SWISSE STUDENT HD

Product Type	Single Medicine Product	Effective date	4/10/2007 11:00:00 PM
---------------------	-------------------------	-----------------------	-----------------------

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

If symptoms persist consult your healthcare practitioner (or words to that effect).,

Contains [insert name of ingredient] (or words to that effect).,

Standard Indications

Helps relieve nervous tension, stress and mild anxiety. [Warning S required],

Beneficial during times of stress. [Warning S required]

Specific Indications

Vitamin supplement with added minerals and herbs to help perform in peak condition. A vitamin, mineral and herbal supplement formulated to address the needs of students in today's demanding, competitive environment. The herbs in Swisse Student HD may be of benefit in times of stress, or when peak condition and stamina are desired. A special formulation designed to help improve stress adaptation. The herbs have been especially chosen for their beneficial effects in providing relief of nervous tension, mild anxiety and stress tension.

Additional Product information

Pack Size/Poison information

Pack Size

Components

1. COMPONENT ONE

Dosage Form

Route of Administration

Visual Identification

Active Ingredients

Poison Schedule

Capsule, hard

Oral

Avena sativa	50 mg
Equivalent: Avena sativa (Fresh)	500 mg
Calcium pantothenate	25 mg
Calcium phosphate	160 mg
Cyanocobalamin	10 microgram
Ginkgo biloba	5 mg
Equivalent: Ginkgo biloba (Dry)	250 mg
Magnesium phosphate	130 mg
Nicotinamide	10 mg
Panax ginseng	35 mg
Equivalent: Panax ginseng (Dry)	350 mg
Potassium phosphate - dibasic	65 mg
Pyridoxine hydrochloride	10 mg
Riboflavine	15 mg
Smilax ornata	12.5 mg
Equivalent: Smilax ornata (Dry)	50 mg
Thiamine nitrate	10 mg
Zinc amino acid chelate	25 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Public Summary

Summary for ARTG Entry:	109294	Swisse Ultiboost Sleep
ARTG entry for	Medicine Listed	
Sponsor	Swisse Wellness Pty Ltd	
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia	
ARTG Start Date	20/09/2004	
Product category	Medicine	
Status	Revoked	
Approval area	Listed Medicines	

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at <http://www.tga.gov.au/industry/cm-colourings-oral-use.htm>, as amended from time to time.

Products

1. Swisse Ultiboost Sleep

Product Type	Single Medicine Product	Effective date	10/12/2009 10:39:18 AM
---------------------	-------------------------	-----------------------	------------------------

Warnings

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Helps relieve nervous tension, stress and mild anxiety. [Warning S required],
Help reduce effects of mild anxiety and nervous tension. [Warning S required],
Aids, assists or helps in the maintenance or improvement of general well-being.

Specific Indications

Can't sleep? Swisse Ultiboost SLEEP is based on the assessment of clinical studies and contains scientifically validated ingredients shown to act quickly and assist you to sleep like a baby and wake up refreshed.
Swisse Ultiboost SLEEP is a combination of herbs clinically proven to promote calmness and relaxation, and to assist in relieving nervous tension and promoting natural, restful sleep. Swisse Ultiboost SLEEP contains ingredients shown to decrease sleep latency (the time taken to fall asleep), assist with reducing symptoms such as mild anxiety and stress and minimise sleep challenges.

Additional Product information

Pack Size/Poison information

Pack Size	Poison Schedule
Components	
1. Formulation 1	
Dosage Form	Tablet, film coated
Route of Administration	Oral
Visual Identification	
Active Ingredients	

Anemarrhena asphodeloides	10 mg
Glycyrrhiza glabra	12.5 mg
Humulus lupulus	26.67 mg
Magnesium orotate	100 mg
Poria cocos	10 mg
Valeriana officinalis	325 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Public Summary

Summary for ARTG Entry:	114871 Imunxl
ARTG entry for	Medicine Listed
Sponsor	Swisse Wellness Pty Ltd
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia
ARTG Start Date	30/11/2004
Product category	Medicine
Status	Revoked
Approval area	Listed Medicines

Conditions

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.,

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Office of Complementary Medicines, Therapeutic Goods Administration, upon request.,

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.,

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.,

The sponsor shall not supply the listed medicine after the expiry date of the goods.,

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.,

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Therapeutic Goods Act 1989, shall be only those included in the list of 'Colourings permitted in medicines for oral use' available at <http://www.tga.gov.au/industry/cm-colourings-oral-use.htm>, as amended from time to time.

Products

1. Imunxl

Product Type	Single Medicine Product	Effective date	12/04/2005
---------------------	-------------------------	-----------------------	------------

Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.,

WARNING: May be dangerous if taken in large amounts or for a long period. OR WARNING: Contains zinc which may be dangerous if taken in large amounts or for a long period (or words to that effect).,

If coughing persists consult your doctor (or a healthcare professional) (or words to that effect).,

Adults only. OR Not to be used in children under two years of age without medical advice (or words to that effect).,

Adults only. OR Not to be used in children under two years of age without medical advice (or words to that effect).,

If symptoms persist consult your healthcare practitioner (or words to that effect).

Standard Indications

Temporary relief of coughs. [Warnings COU1 and COU2 required],

Relief of coughs. [Warnings COU1 and COU2 required],

Relief of the symptoms of influenza/flu. [Warnings S and COLD required],

Can assist in the treatment of flu by reducing the severity and duration of symptoms. [Warnings S and COLD required],

Relief of mucous congestion. [Warnings S and COLD required],

Relief of symptoms of mild upper respiratory infections. [Warnings S and COLD required],

Helps fight mild upper respiratory complaints. [Warnings S and COLD required],

For the symptomatic relief of recurrent upper respiratory tract infections. [Warnings S and COLD required],

May assist in the management of recurrent upper respiratory tract infections. [Warnings S and COLD required],

Aids, assists or helps in the maintenance or improvement of general well-being.,

Relief of the symptoms of allergies. [Warning S required],

Relief of the symptoms of colds. [Warnings S and COLD required],

May assist in the management of upper respiratory tract infections. [Warnings S and COLD required],

May help reduce the severity of the symptoms of colds. [Warnings S and COLD required],

May reduce the severity of colds. [Warning COLD required],
 May reduce the duration of colds. [Warning COLD required],
 May reduce the severity and duration of colds. [Warning COLD required],
 For relief of mucous congestion. [Warnings S and COLD required],
 For the symptomatic relief of upper respiratory tract infections. [Warnings S and COLD required]

Specific Indications

CLINICALS IMUNXL by Swisse has been developed by a professor and contains ingredients traditionally used and supported by clinical studies to assist in immune challenging conditions such as colds or flu. IMUNXL is based on the assessment of traditional use and clinical studies, which showed that certain ingredients in IMUNXL provide relief from the symptoms associated with colds and flu such as a blocked or runny nose, dry cough, and mucous congestion. Used as directed, IMUNXL may deliver positive results relatively quickly. Best used when first symptoms occur or when your body is most vulnerable such as prior to winter or contact with sick people. For better results: IMUNXL may be effective when used on its own, however we recommend you use this product in conjunction with Swisse Women's or Men's Ultivite, which act as a "foundation" to provide the body with the important nutrients necessary for general wellbeing.

Additional Product Information**Pack Size/Poison information****Pack Size****Components****1. Medicine Component****Dosage Form****Route of Administration****Visual Identification****Active Ingredients**

Calcium ascorbate

Citrus bioflavonoids extract

Cupric sulfate pentahydrate

Magnesium aspartate

Olea europaea

Equivalent: Olea europaea (Dry)

Zinc sulfate monohydrate

Poison Schedule

Tablet, film coated

Oral

605.34 mg

20 mg

3.93 mg

250 mg

55.56 mg

250 mg

68.61 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Public Summary

Summary for ARTG Entry: 76578 WOMEN'S ULTIVITE MULTI-VITAMIN MINERAL & ANTI- OXIDANT WITH HERBS FORMULA 1 DIETARY SUPPLEMENT capsule bottle

ARTG entry for Medicine Listed (Export Only)
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 19/10/2000
Product category Medicine
Status Revoked
Approval area Export only Medicines

Conditions

Except where the sponsor has been contracted by an overseas party to manufacture the goods and that party will be responsible for placing the goods on the market in countries other than Australia, the sponsor must have and shall retain, while the goods remain listed, evidence necessary to substantiate and support the accuracy of the indications in relation to the listed goods and, upon the request of the Head, Office of Medicines Authorisation, Therapeutic Goods Administration, shall produce such evidence to the Director.,

The conditions applying to these goods when they are exported from Australia are given below:

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No. 8 and condition No. 9.,

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No.11

Products

1. WOMEN'S ULTIVITE MULTI-VITAMIN MINERAL & ANTI- OXIDANT WITH HERBS FORMULA 1 DIETARY SUPPLEMENT

Product Type Single Medicine Product **Effective date** 13/11/2008

Warnings

No Warnings included on Record

Standard Indications**Specific Indications**

Designed to meet women's nutritional needs and help in the maintenance or improvement of general well-being.

Additional Product Information**Container information**

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	2 Years	Store below 30 degrees Celsius	Not recorded	Not recorded

Pack Size/Poison information**Pack Size**

120 capsules,
60 capsules

Poison Schedule

Not scheduled. Not considered by committee,
Not scheduled. Not considered by committee

Components**1. Medicine Component****Dosage Form**

Capsule, hard

Route of Administration

Oral

Visual Identification

Amber coloured powder in a clear hard gelatin capsule. Size 0 Length 21.4 mm Width 7.64 mm

Active Ingredients**Apium graveolens**

1 mg

Equivalent: Apium graveolens (Dry)

10 mg

Arctostaphylos uva-ursi

3.12 mg

Equivalent: Arctostaphylos uva-ursi (Dry)

12.5 mg

Astragalus membranaceus

2.5 mg

Equivalent: Astragalus membranaceus (Dry)

25 mg

Avena sativa

25 mg

Equivalent: Avena sativa (Fresh)	250 mg
Bioflavonoids	20 mg
Biotin	25 microgram
Calcium ascorbate dihydrate	100 mg
Calcium citrate	50 mg
Calcium pantothenate	37.5 mg
Camellia sinensis	1.67 mg
Equivalent: Camellia sinensis (Dry)	10 mg
Carica papaya	5 mg
Centella asiatica	1.25 mg
Equivalent: Centella asiatica (Dry)	5 mg
Cholecalciferol	2.5 microgram
Equivalent: Cholecalciferol (Dry)	1 mg
Choline bitartrate	12.5 mg
Chromium picolinate	25 microgram
Copper gluconate	208.5 microgram
Crataegus monogyna	3.75 mg
Equivalent: Crataegus monogyna (Dry)	15 mg
Cyanocobalamin	25 microgram
Cynara scolymus	6.25 mg
Equivalent: Cynara scolymus (Fresh)	25 mg
d-alpha-Tocopheryl acid succinate	20.66 mg
Dunaliella salina	33.33 mg
Equivalent: Dunaliella salina (Fresh)	60 mg
Eleutherococcus senticosus	1.25 mg
Equivalent: Eleutherococcus senticosus (Dry)	12.5 mg
Equisetum arvense	3.75 mg
Equivalent: Equisetum arvense (Dry)	15 mg
Ferrous fumarate	7.55 mg
Foeniculum vulgare	1.7 mg
Equivalent: Foeniculum vulgare (Dry)	7.5 mg
Folic acid	150 microgram
Ginkgo biloba	50 microgram
Equivalent: Ginkgo biloba (Dry)	2.5 mg
Glycyrrhiza glabra	1.25 mg
Equivalent: Glycyrrhiza glabra (Dry)	5 mg
Inositol	12.5 mg
Lycopersicon esculentum	1 mg
Equivalent: Lycopersicon esculentum (Dry)	20 mg
Lysine hydrochloride	25 mg
Magnesium oxide - heavy	42.5 mg
Manganese amino acid chelate	8 mg
Matricaria recutita	1.88 mg
Equivalent: Matricaria recutita (Dry)	7.5 mg
Nicotinamide	25 mg
Petroselinum crispum	5 g
Potassium iodide	32.7 microgram
Potassium sulfate	2.23 mg
Pyridoxine hydrochloride	25 mg
Riboflavine	25 mg
Selenomethionine	32.5 microgram
Silybum marianum	357 microgram
Equivalent: Silybum marianum (Dry)	25 mg
Spearmint Oil	750 microgram
Tagetes erecta	500 microgram
Equivalent: Tagetes erecta (Dry)	10 mg
Thiamine hydrochloride	25 mg

Ubidecarenone	500 microgram
Vaccinium myrtillus	125 microgram
Equivalent: Vaccinium myrtillus (Fresh)	12.5 mg
Vitis vinifera	4.17 mg
Equivalent: Vitis vinifera (Dry)	500 mg
Zinc amino acid chelate	12.5 mg
Zingiber officinale	1.5 mg
Equivalent: Zingiber officinale (Dry)	7.5 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Public Summary

Summary for ARTG Entry:	79766	SWISSE WOMEN'S ULTIBOOST MINERAL & HERBAL PRE-EVENT FORMULA Tablet - film coated bottle
ARTG entry for	Medicine Listed	
Sponsor	Swisse Wellness Pty Ltd	
Postal Address	36-38 Gipps Street, COLLINGWOOD, VIC, 3066 Australia	
ARTG Start Date	7/08/2001	
Product category	Medicine	
Status	Revoked	
Approval area	Listed Medicines	

Conditions

Except where the sponsor has been contracted by an overseas party to manufacture the goods and that party will be responsible for placing the goods on the market in countries other than Australia, the sponsor must have and shall retain, while the goods remain listed, evidence necessary to substantiate and support the accuracy of the indications in relation to the listed goods and, upon the request of the Head, Office of Medicines Authorisation, Therapeutic Goods Administration, shall produce such evidence to the Director.,

A copy of a signed and dated certificate of analysis, which is not more than six months old, for the first batch of goods manufactured is to be provided to the Head, Listing Treaties & Export Section, Chemical & Non Prescription Drug Branch within six months of the date of supply of the goods.

The conditions applying to these goods when they are exported from Australia are given below;

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No. 8 and condition No. 9.

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No.11,

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.,

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995.

Products

1. SWISSE WOMEN'S ULTIBOOST MINERAL & HERBAL PRE-EVENT FORMULA

Product Type	Single Medicine Product	Effective date	4/02/2003
---------------------	-------------------------	-----------------------	-----------

Warnings

Contains maltodextrin (or words to that effect).,

If symptoms persist, seek the advice of a healthcare professional.

Standard Indications

May assist in maintaining peripheral circulation and promoting general health.,

Aids or assists in the maintenance of peripheral circulation to relieve cold hands and feet. [Warning S required],

Assisting in the maintenance of blood flow in the hands, feet and legs.,

Aids or assists in the maintenance of peripheral circulation.,

To help maintain blood circulation to the peripheral areas of the body such as the legs, hands and feet.,

Beneficial during times of stress. [Warning S required],

Aids, assists or helps in the maintenance or improvement of general well-being.,

May assist blood circulation

Specific Indications

Swisse Women's UltiBoost, to boost stamina and memory for peak performance, has been designed by a professor to be used as a companion with Swisse Women's Ultivite Formula 1 when an extra boost is required. Swisse Women's UltiBoost can also prepare you for periods in your life where you will be demanding more of your body and faculties such as working overtime, travelling or giving presentations. It's all about assisting you to perform in peak condition and enhancing mental alertness, so Swisse Women's UltiBoost should be taken before and during physical and mental exertion. The difference is that unlike Swisse Women's Ultivite Formula 1 that is used daily throughout the year for the maintenance of general wellbeing, you only need to use Swisse Women's UltiBoost when you feel you need that 'extra boost'.

Additional Product information

Container information

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	2 Years	Store below 30 degrees Celsius	Not recorded	Not recorded

Pack Size/Poison information

Pack Size

N/A

Poison Schedule

Not scheduled. Not considered by committee

Components**1. COMPONENT ONE****Dosage Form**

Tablet, film coated

Route of Administration

Oral

Visual Identification

Extra large oval yellow mustard film coated tablet Length 23.20 mm Width 10.50 mm

Active Ingredients**Cimicifuga racemosa**

50 mg

Equivalent: Cimicifuga racemosa (Dry)

200 mg

Cimicifuga racemosa**Ginkgo biloba****Ginkgo biloba**

60 mg

Equivalent: Ginkgo biloba (Dry)

3 g

Glutamine

250 mg

Magnesium aspartate

500 mg

Panax ginseng

100 mg

Equivalent: Panax ginseng (Dry)

1 g

Panax ginseng**Schizandra chinensis**

40 mg

Schizandra chinensis

400 mg

Equivalent: Schizandra chinensis (Dry)

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary

Public Summary

Summary for ARTG Entry: 76577 WOMEN'S ULTIVITE MULTI-VITAMIN MINERAL & ANTI- OXIDANT WITH HERBS FORMULA 1 DIETARY SUPPLEMENT

ARTG entry for Medicine Listed (Export Only)
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 19/10/2000
Product category Medicine
Status Revoked
Approval area Export only Medicines

Conditions

Except where the sponsor has been contracted by an overseas party to manufacture the goods and that party will be responsible for placing the goods on the market in countries other than Australia, the sponsor must have and shall retain, while the goods remain listed, evidence necessary to substantiate and support the accuracy of the indications in relation to the listed goods and, upon the request of the Head, Office of Medicines Authorisation, Therapeutic Goods Administration, shall produce such evidence to the Director.,

The conditions applying to these goods when they are exported from Australia are given below;

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No. 8 and condition No. 9.,

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No.11,

The sponsor shall hold stability data to support the claimed shelf life of the listed medicine according to the labelled storage conditions. The sponsor will provide stability data to the Head, Office of Medicines Authorisation, TGA upon request, except where the overseas importer accepts responsibility for stability studies. When an overseas importer accepts responsibility for providing stability data for this product, it is the sponsor's responsibility to ensure that they have a written agreement to this effect from the overseas importer. The sponsor will provide a copy of this agreement to the Head, Office of Medicines Authorisation, TGA upon request.

Products

1. WOMEN'S ULTIVITE MULTI-VITAMIN MINERAL & ANTI- OXIDANT WITH HERBS FORMULA 1 DIETARY SUPPLEMENT

Product Type	Single Medicine Product	Effective date	13/11/2008
--------------	-------------------------	----------------	------------

Warnings

No Warnings included on Record

Standard Indications**Specific Indications**

Designed to meet Women's nutritional needs and help in the maintenance or improvement of general well-being.

Additional Product Information**Container Information**

Type	Material	Life Time	Temperature	Closure	Conditions
Jar/Can	Not recorded	3 Years	Not recorded	Not recorded	Not recorded

Pack Size/Poison Information**Pack Size**

30 tablets,
60 tablets

Poison Schedule

Not scheduled. Not considered by committee,
Not scheduled. Not considered by committee

Components**1. Medicine Component****Dosage Form**

Tablet, film coated

Route of Administration

Oral

Visual Identification

Extra large oval shaped light pink film coated tablet Length 23.2 mm Width 10.5 mm

Active Ingredients

Apium graveolens	2 mg
Equivalent: Apium graveolens (Dry)	20 mg
Arctostaphylos uva-ursi	6.25 mg
Equivalent: Arctostaphylos uva-ursi (Dry)	25 mg

Astragalus membranaceus	5 mg
Equivalent: Astragalus membranaceus (Dry)	50 mg
Avena sativa	50 mg
Equivalent: Avena sativa (Fresh)	500 mg
Biotin	50 microgram
Calcium ascorbate dihydrate	200 mg
Calcium citrate	200 mg
Calcium pantothenate	75 mg
Camellia sinensis	3.34 mg
Equivalent: Camellia sinensis (Dry)	20 mg
Carica papaya	10 mg
Centella asiatica	2.5 mg
Equivalent: Centella asiatica (Dry)	10 mg
Choline bitartrate	25 mg
Chromium picolinate	50 microgram
Citrus bioflavonoids extract	40 mg
Copper gluconate	417 microgram
Crataegus monogyna	7.5 mg
Equivalent: Crataegus monogyna (Dry)	30 mg
Cyanocobalamin	50 microgram
Cynara scolymus	12.5 mg
Equivalent: Cynara scolymus (Fresh)	50 mg
d-alpha-Tocopheryl acid succinate	41.33 mg
Eleutherococcus senticosus	2.5 mg
Equivalent: Eleutherococcus senticosus (Dry)	25 mg
Equisetum arvense	7.5 mg
Equivalent: Equisetum arvense (Dry)	30 mg
Ferrous fumarate	16.01 mg
Foeniculum vulgare	3.41 mg
Equivalent: Foeniculum vulgare (Dry)	15 mg
Folic acid	300 microgram
Ginkgo biloba	100 microgram
Equivalent: Ginkgo biloba (Dry)	5 mg
Glycyrrhiza glabra	2.5 mg
Equivalent: Glycyrrhiza glabra (Dry)	10 mg
Inositol	25 mg
Lysine hydrochloride	50 mg
Magnesium oxide - heavy	81.46 mg
Manganese amino acid chelate	16 mg
Matricaria recutita	3.75 mg
Equivalent: Matricaria recutita (Dry)	15 mg
Nicotinamide	50 mg
Petroselinum crispum	10 mg
Potassium iodide	66 microgram
Potassium sulfate	4.45 mg
Pyridoxine hydrochloride	50 mg
Riboflavin	50 mg
Selenomethionine	65 microgram
Spearmint Oil	1.5 mg
Thiamine hydrochloride	50 mg
Ubidecarenone	1 mg
Zinc amino acid chelate	25 mg
Zingiber officinale	3 mg
Equivalent: Zingiber officinale (Dry)	15 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

CANCELLED

Public Summary

Public Summary

Summary for ARTG Entry: 76576 WOMEN'S ULTIVITE MULTI-VITAMIN MINERAL & ANTI- OXIDANT WITH HERBS NO IRON OR IODINE
DIETARY SUPPLEMENT tablet jar

ARTG entry for Medicine Listed (Export Only)
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 19/10/2000
Product category Medicine
Status Revoked
Approval area Export only Medicines

Conditions

Except where the sponsor has been contracted by an overseas party to manufacture the goods and that party will be responsible for placing the goods on the market in countries other than Australia, the sponsor must have and shall retain, while the goods remain listed, evidence necessary to substantiate and support the accuracy of the indications in relation to the listed goods and, upon the request of the Head, Office of Medicines Authorisation, Therapeutic Goods Administration, shall produce such evidence to the Director..

The conditions applying to these goods when they are exported from Australia are given below:

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No. 8 and condition No. 9.,

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No.11

Products

1. WOMEN'S ULTIVITE MULTI-VITAMIN MINERAL & ANTI- OXIDANT WITH HERBS NO IRON OR IODINE DIETARY SUPPL

Product Type Single Medicine Product **Effective date** 13/11/2008

Warnings

No Warnings included on Record

Standard Indications**Specific Indications**

Designed to meet nutritional needs of women who have been diagnosed with Iron overload (hemochromatosis), or should not take iodine.

Additional Product Information**Container Information**

Type	Material	Life Time	Temperature	Closure	Conditions
Jar/Can	Not recorded	2-Years	Store below 30 degrees Celsius	Not recorded	Not recorded

Pack Size/Poison Information**Pack Size**

60 tablets

30 tablets

Components

1 Medicine Component

Dosage Form**Route of Administration****Visual Identification****Active Ingredients****Apium graveolens**

Equivalent: Apium graveolens (Dry)

Arctostaphylos uva-ursi

Equivalent: Arctostaphylos uva-ursi (Dry)

Astragalus membranaceus

Equivalent: Astragalus membranaceus (Dry)

Avena sativa

Equivalent: Avena sativa (Fresh)

Poison Schedule

Not scheduled. Not considered by committee,

Not scheduled. Not considered by committee

Tablet, film coated

Oral

Extra large oval white film coated tablet. Length 23.2 mm Width 10.5 mm

Bioflavonoids	40 mg
Biotin	50 microgram
Calcium ascorbate dihydrate	50 mg
Calcium citrate	200 mg
Calcium pantothenate	75 mg
Camellia sinensis	3.34 mg
Equivalent: Camellia sinensis (Dry)	20 mg
Carica papaya	5 mg
Centella asiatica	2.5 mg
Equivalent: Centella asiatica (Dry)	10 mg
Cholecalciferol	5 microgram
Choline bitartrate	25 mg
Chromium picolinate	50 microgram
Copper gluconate	417 microgram
Crataegus monogyna	7.5 mg
Equivalent: Crataegus monogyna (Dry)	30 mg
Cyanocobalamin	50 microgram
Cynara scolymus	12.5 mg
Equivalent: Cynara scolymus (Fresh)	50 mg
d-alpha-Tocopheryl acid succinate	37.19 mg
Dunaliella salina	66.67 mg
Equivalent: Dunaliella salina (Fresh)	120 mg
Eleutherococcus senticosus	2.5 mg
Equivalent: Eleutherococcus senticosus (Dry)	25 mg
Equisetum arvense	7.5 mg
Equivalent: Equisetum arvense (Dry)	30 mg
Foeniculum vulgare	3.41 mg
Equivalent: Foeniculum vulgare (Dry)	15 mg
Folic acid	300 microgram
Ginkgo biloba	100 microgram
Equivalent: Ginkgo biloba (Dry)	5 mg
Glycyrrhiza glabra	2.5 mg
Equivalent: Glycyrrhiza glabra (Dry)	10 mg
Inositol	25 mg
Lycopersicon esculentum	2 mg
Equivalent: Lycopersicon esculentum (Dry)	40 mg
Magnesium oxide - heavy	92 mg
Manganese amino acid chelate	16 mg
Matricaria recutita	3.75 mg
Equivalent: Matricaria recutita (Dry)	15 mg
Nicotinamide	50 mg
Petroselinum crispum	5 mg
Potassium sulfate	4.45 mg
Pyridoxine hydrochloride	50 mg
Riboflavine	50 mg
Selenomethionine	65 microgram
Silybum marianum	14.29 mg
Equivalent: Silybum marianum (Dry)	1 g
Spearmint Oil	1.7 mg
Tagetes erecta	1 mg
Equivalent: Tagetes erecta (Dry)	20 mg
Thiamine hydrochloride	50 mg
Tocopherols concentrate - mixed (low-alpha type)	3.36 mg
Ubidecarenone	1 mg
Vaccinium myrtillus	250 microgram
Equivalent: Vaccinium myrtillus (Fresh)	25 mg
Vitis vinifera	8.34 mg

Equivalent: <i>Vitis vinifera</i> (Dry)	1 g
Zinc amino acid chelate	25 mg
Zingiber officinale	3 mg
Equivalent: Zingiber officinale (Dry)	15 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

CANCELLED

Public Summary

Public Summary

Summary for ARTG Entry: 76575 WOMEN'S ULTIVITE MULTI-VITAMIN MINERAL & ANTI- OXIDANT WITH HERBS NO IRON OR IODINE
DIETARY SUPPLEMENT capsule bottle

ARTG entry for Medicine Listed (Export Only)
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 19/10/2000
Product category Medicine
Status Revoked
Approval area Export only Medicines

Conditions

Except where the sponsor has been contracted by an overseas party to manufacture the goods and that party will be responsible for placing the goods on the market in countries other than Australia, the sponsor must have and shall retain, while the goods remain listed, evidence necessary to substantiate and support the accuracy of the indications in relation to the listed goods and, upon the request of the Head, Office of Medicines Authorisation, Therapeutic Goods Administration, shall produce such evidence to the Director.,

The conditions applying to these goods when they are exported from Australia are given below;

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No. 8 and condition No. 9.,

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No.11

Products

1. WOMEN'S ULTIVITE MULT-VITAMIN MINERAL & ANTI- OXIDANT WITH HERBS NO IRON OR IODINE DIETARY SUPPL

Product Type Single Medicine Product **Effective date** 13/11/2008

Warnings

No Warnings included on Record

Standard Indications**Specific Indications**

Designed to meet nutritional needs of women who have been diagnosed with iron overload (hemochromatosis) or should not take iodine.

Additional Product information**Container information**

Type	Material	Life time	Temperature	Closure	Conditions
Bottle	Not recorded	2 Years	Store below 30 degrees Celsius	Not recorded	Not recorded

Pack Size/Poison information**Pack Size**

120 capsules,
60 capsules

Components**1. Medicine Component****Dosage Form****Route of Administration****Visual Identification****Poison Schedule**

Not scheduled. Not considered by committee,
Not scheduled. Not considered by committee

Capsule, hard

Oral

Amber coloured powder in a clear hard gelatin capsule Size 0 Length 21.4 mm Width 7.64 mm

Active Ingredients

Apium graveolens	1 mg
Equivalent: Apium graveolens (Dry)	10 mg
Arctostaphylos uva-ursi	3.12 mg
Equivalent: Arctostaphylos uva-ursi (Dry)	12.5 mg
Astragalus membranaceus	2.5 mg
Equivalent: Astragalus membranaceus (Dry)	25 mg
Avena sativa	25 mg

Equivalent: Avena sativa (Fresh)	250 mg
Bioflavonoids	20 mg
Biotin	25 microgram
Calcium ascorbate dihydrate	25 mg
Calcium carbonate	55.55 mg
Calcium pantothenate	37.5 mg
Camellia sinensis	1.67 mg
Equivalent: Camellia sinensis (Dry)	10 mg
Carica papaya	2.5 mg
Centella asiatica	1.25 mg
Equivalent: Centella asiatica (Dry)	5 mg
Cholecalciferol	2.5 microgram
Choline bitartrate	12.5 mg
Chromium picolinate	25 microgram
Copper gluconate	209 microgram
Crataegus monogyna	3.75 mg
Equivalent: Crataegus monogyna (Dry)	15 mg
Cyanocobalamin	25 microgram
Cynara scolymus	6.25 mg
Equivalent: Cynara scolymus (Fresh)	25 mg
d-alpha-Tocopheryl acid succinate	18.6 mg
Dunaliella salina	33.33 mg
Equivalent: Dunaliella salina (Fresh)	60 mg
Eleutherococcus senticosus	1.25 mg
Equivalent: Eleutherococcus senticosus (Dry)	12.5 mg
Equisetum arvense	3.75 mg
Equivalent: Equisetum arvense (Dry)	15 mg
Foeniculum vulgare	1.7 mg
Equivalent: Foeniculum vulgare (Dry)	7.5 mg
Folic acid	150 microgram
Ginkgo biloba	50 microgram
Equivalent: Ginkgo biloba (Dry)	2.5 mg
Glycyrrhiza glabra	1.25 mg
Equivalent: Glycyrrhiza glabra (Dry)	5 mg
Inositol	12.5 mg
Lycopersicon esculentum	1 mg
Equivalent: Lycopersicon esculentum (Dry)	20 mg
Magnesium oxide - heavy	46 mg
Manganese amino acid chelate	8 mg
Matricaria recutita	1.88 mg
Equivalent: Matricaria recutita (Dry)	7.5 mg
Nicotinamide	25 mg
Petroselinum crispum	2.5 mg
Potassium sulfate	2.23 mg
Pyridoxine hydrochloride	25 mg
Riboflavin	25 mg
Selenomethionine	32.5 microgram
Silybum marianum	7.14 mg
Equivalent: Silybum marianum (Dry)	500 mg
Spearmint Oil	750 microgram
Tagetes erecta	500 microgram
Equivalent: Tagetes erecta (Dry)	10 mg
Thiamine hydrochloride	25 mg
Tocopherols concentrate - mixed (low-alpha type)	1.68 mg
Ubidecarenone	500 microgram
Vaccinium myrtillus	125 microgram
Equivalent: Vaccinium myrtillus (Fresh)	12.5 mg

Vitis vinifera	4.17 mg
Equivalent: Vitis vinifera (Dry)	500 mg
Zinc amino acid chelate	12.5 mg
Zingiber officinale	1.5 mg
Equivalent: Zingiber officinale (Dry)	7.5 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

CANCELLED

Public Summary

Public Summary

Summary for ARTG Entry: 76573 MEN'S ULTIVITE MULTI-VITAMIN MINERAL & ANTI- OXIDANT WITH HERBS FORMULA 1 DIETARY SUPPLEMENT

ARTG entry for Medicine Listed (Export Only)
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 19/10/2000
Product category Medicine
Status Revoked
Approval area Export only Medicines

Conditions

Except where the sponsor has been contracted by an overseas party to manufacture the goods and that party will be responsible for placing the goods on the market in countries other than Australia, the sponsor must have and shall retain, while the goods remain listed, evidence necessary to substantiate and support the accuracy of the indications in relation to the listed goods and, upon the request of the Head, Office of Medicines Authorisation, Therapeutic Goods Administration, shall produce such evidence to the Director.,

The conditions applying to these goods when they are exported from Australia are given below.,

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No. 8 and condition No. 9.,

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No.11,

The sponsor shall hold stability data to support the claimed shelf life of the listed medicine according to the labelled storage conditions. The sponsor will provide stability data to the Head, Office of Medicines Authorisation, TGA upon request, except where the overseas importer accepts responsibility for stability studies. When an overseas importer accepts responsibility for providing stability data for this product, it is the sponsor's responsibility to ensure that they have a written agreement to this effect from the overseas importer. The sponsor will provide a copy of this agreement to the Head, Office of Medicines Authorisation, TGA upon request.

Products

1. MEN'S ULTIVITE MULTI-VITAMIN MINERAL & ANTI- OXIDANT WITH HERBS FORMULA 1 DIETARY SUPPLEMENT

Product Type Single Medicine Product **Effective date** 13/11/2008

Warnings

No Warnings included on Record

Standard Indications**Specific Indications**

Designed to meet man's nutritional needs and help in the maintenance or improvement of general well-being.

Additional Product Information**Pack Size/Poison information****Pack Size**

60 tablets

30 tablets

Components**1. Medicine Component****Dosage Form****Route of Administration****Visual Identification****Active Ingredients****Apium graveolens**

Equivalent: Apium graveolens (Dry)

Astragalus membranaceus

Equivalent: Astragalus membranaceus (Dry)

Avena sativa

Equivalent: Avena sativa (Fresh)

Barosma betulina

Equivalent: Barosma betulina (Dry)

Poison Schedule

Not scheduled. Not considered by committee,

Not scheduled. Not considered by committee

Tablet, film coated

Oral

Extra large oval green film coated tablet Length 23.2 mm Width 10.5 mm

Berberis vulgaris	2.5 mg
Equivalent: Berberis vulgaris (Dry)	15 mg
Biotin	50 microgram
Calcium ascorbate dihydrate	200 mg
Calcium citrate	100 mg
Calcium pantothenate	70 mg
Camellia sinensis	3.34 mg
Equivalent: Camellia sinensis (Dry)	20 mg
Carica papaya	10 mg
Centella asiatica	12.5 mg
Equivalent: Centella asiatica (Dry)	50 mg
Choline bitartrate	25 mg
Chromium picolinate	50 microgram
Citrus bioflavonoids extract	40 mg
Copper gluconate	200 microgram
Crataegus monogyna	25 mg
Equivalent: Crataegus monogyna (Dry)	100 mg
Cyanocobalamin	30 microgram
Cynara scolymus	12.5 mg
Equivalent: Cynara scolymus (Fresh)	50 mg
Equisetum arvense	7.5 mg
Equivalent: Equisetum arvense (Dry)	30 mg
Ferrous fumarate	9.13 mg
Foeniculum vulgare	3.41 mg
Equivalent: Foeniculum vulgare (Dry)	15 mg
Folic acid	300 microgram
Ginkgo biloba	2 mg
Equivalent: Ginkgo biloba (Dry)	100 mg
Inositol	25 mg
Lysine hydrochloride	50 mg
Magnesium oxide - heavy	100 mg
Manganese amino acid chelate	12 mg
Nicotinamide	30 mg
Panax ginseng	16.67 mg
Equivalent: Panax ginseng (Dry)	50 mg
Petroselinum crispum	10 mg
Potassium iodide	66 microgram
Potassium sulfate	8.92 mg
Pyridoxine hydrochloride	30 mg
Riboflavin	30 mg
Selenomethionine	65 microgram
Serenoa repens	20 mg
Equivalent: Serenoa repens (Dry)	200 mg
Smilax officinalis	12.5 mg
Equivalent: Smilax officinalis (Dry)	50 mg
Spearmint Oil	1.5 mg
Thiamine hydrochloride	30 mg
Turnera diffusa	24 mg
Equivalent: Turnera diffusa (Dry)	120 mg
Tyrosine	1 mg
Ubidecarenone	1 mg
Zinc amino acid chelate	30 mg
Zingiber officinale	1 mg
Equivalent: Zingiber officinale (Dry)	5 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

CANCELLED

Public Summary

Public Summary

Summary for ARTG Entry: 76574 MEN'S ULTIVITE MULTI-VITAMIN MINERAL & ANTI- OXIDANT WITH HERBS FORMULA 1 DIETARY SUPPLEMENT capsule bottle

ARTG entry for Medicine Listed (Export Only)
Sponsor Swisse Wellness Pty Ltd
Postal Address 36-38 Gipps Street, COLLINGWOOD, VIC, 3066
 Australia
ARTG Start Date 19/10/2000
Product category Medicine
Status Revoked
Approval area Export only Medicines

Conditions

Except where the sponsor has been contracted by an overseas party to manufacture the goods and that party will be responsible for placing the goods on the market in countries other than Australia, the sponsor must have and shall retain, while the goods remain listed, evidence necessary to substantiate and support the accuracy of the indications in relation to the listed goods and, upon the request of the Head, Office of Medicines Authorisation, Therapeutic Goods Administration, shall produce such evidence to the Director.,

The conditions applying to these goods when they are exported from Australia are given below.,

Conditions applicable to all therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No. 8 and condition No. 9.,

Conditions applicable to the relevant category and class of therapeutic goods as specified in the document "Standard Conditions Applying to Registered or Listed Therapeutic Goods Under Section 28 of the Therapeutic Goods Act 1989" effective 1 July 1995, other than condition No.11

Products

1. MEN'S ULTIVITE MULTI-VITAMIN MINERAL & ANTI- OXIDANT WITH HERBS FORMULA DIETARY SUPPLEMENT

Product Type Single Medicine Product **Effective date** 13/11/2008

Warnings

No Warnings included on Record

Standard Indications**Specific Indications**

Designed to meet men's nutritional needs and help in the maintenance or improvement of general well-being.

Additional Product Information**Container information**

Type	Material	Life Time	Temperature	Closure	Conditions
Bottle	Not recorded	2 Years	Store below 30 degrees Celsius	Not recorded	Not recorded

Pack Size/Poison information**Pack Size**

120 capsules,
60 capsules

Components**1. Medicine Component****Dosage Form****Route of Administration****Visual Identification****Poison Schedule**

Not scheduled. Not considered by committee,
Not scheduled. Not considered by committee

Capsule, hard

Oral

Amber coloured powder in a clear hard gelatin capsule Size 0 Length 21.4 mm Width 7.64 mm

Active Ingredients

Apium graveolens	1 mg
Equivalent: Apium graveolens (Dry)	10 mg
Astragalus membranaceus	2.5 mg
Equivalent: Astragalus membranaceus (Dry)	.25 mg
Avena sativa	25 mg
Equivalent: Avena sativa (Fresh)	250 mg
Barosma betulina	1.25 mg

Equivalent: Barosma betulina (Dry)	5 mg
Berberis vulgaris	1.25 mg
Equivalent: Berberis vulgaris (Dry)	7.5 mg
Bioflavonoids	20 mg
Biotin	25 microgram
Calcium ascorbate dihydrate	100 mg
Calcium citrate	50 mg
Calcium pantothenate	35 mg
Camellia sinensis	1.67 mg
Equivalent: Camellia sinensis (Dry)	10 mg
Carica papaya	5 mg
Centella asiatica	6.25 mg
Equivalent: Centella asiatica (Dry)	25 mg
Cholecalciferol	2.5 microgram
Choline bitartrate	12.5 mg
Chromium picolinate	25 microgram
Copper gluconate	100 microgram
Crataegus monogyna	12.5 mg
Equivalent: Crataegus monogyna (Dry)	50 mg
Cyanocobalamin	15 microgram
Cynara scolymus	6.25 mg
Equivalent: Cynara scolymus (Fresh)	25 mg
d-alpha-Tocopheryl acid succinate	20.66 mg
Dunaliella salina	33.33 mg
Equivalent: Dunaliella salina (Fresh)	60 mg
Equisetum arvense	3.75 mg
Equivalent: Equisetum arvense (Dry)	15 mg
Ferrous fumarate	4.56 mg
Foeniculum vulgare	1.7 mg
Equivalent: Foeniculum vulgare (Dry)	7.5 mg
Folic acid	150 microgram
Ginkgo biloba	1 mg
Equivalent: Ginkgo biloba (Dry)	50 mg
Inositol	12.5 mg
Lycopersicon esculentum	1 mg
Equivalent: Lycopersicon esculentum (Dry)	20 mg
Lysine hydrochloride	25 mg
Magnesium oxide - heavy	50 mg
Manganese amino acid chelate	6 mg
Nicotinamide	15 mg
Panax ginseng	8.33 mg
Equivalent: Panax ginseng (Dry)	25 mg
Petroselinum crispum	5 mg
Potassium iodide	33 microgram
Potassium sulfate	4.46 mg
Pyridoxine hydrochloride	15 mg
Riboflavin	15 mg
Selenomethionine	32.5 microgram
Serenoa repens	10 mg
Equivalent: Serenoa repens (Dry)	100 mg
Silybum marianum	357 microgram
Equivalent: Silybum marianum (Dry)	25 mg
Smilax officinalis	6.25 mg
Equivalent: Smilax officinalis (Dry)	25 mg
Spearmint Oil	750 microgram
Tagetes erecta	500 microgram
Equivalent: Tagetes erecta (Dry)	10 mg

Thiamine hydrochloride	15 mg
Turnera diffusa	12 mg
Equivalent: Turnera diffusa (Dry)	60 mg
Tyrosine	500 microgram
Ubidecarenone	500 microgram
Vaccinium myrtillus	125 microgram
Equivalent: Vaccinium myrtillus (Fresh)	12.5 mg
Vitis vinifera	4.17 mg
Equivalent: Vitis vinifera (Dry)	500 mg
Zinc amino acid chelate	15 mg
Zingiber officinale	500 microgram
Equivalent: Zingiber officinale (Dry)	2.5 mg

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary